FINWIRES · TerminalLIVE
FINWIRES

HKG:9887

8 stories mentioning HKG:9887Updated 1d ago

Every FINWIRES story that references HKG:9887, newest first.

Asia

Nanjing Leads Biolabs Advances Liver Cancer Drug to Phase 2 Expansion

Nanjing Leads Biolabs (HKG:9887) said its phase II clinical trial of LBL-024 for first-line hepatocellular carcinoma has advanced to the expansion phase after completing the safety run-in assessment, according to a Thursday Hong Kong bourse filing.The company said preliminary data showed that LBL-024, in combination with bevacizumab, demonstrated encouraging efficacy signals, along with a favorable safety profile and good tolerability in patients with liver cancer.

HKG:9887
Asia

Nanjing Leads Biolabs Wins China Trial Nod for Colorectal Cancer Drug

Nanjing Leads Biolabs (HKG:9887) said its investigational cancer therapy LBL-024 received approval from China's National Medical Products Administration to begin clinical trials for the treatment of metastatic colorectal cancer, according to a Monday Hong Kong bourse filing.The approval covers a Phase 1b/2 study evaluating LBL-024, a PD-L1/4-1BB bispecific antibody, in combination therapy for metastatic colorectal cancer.

HKG:9887
Asia

KPC Pharmaceuticals to Divest Stake in Nanjing Leads Biolabs

KPC Pharmaceuticals (SHA:600422) will sell 2.4 million shares it holds in Nanjing Leads Biolabs (HKG:9887) for a total of 132.2 million yuan, according to a Saturday disclosure to the Shanghai bourse.The divestment of the 1.2283% stake will help KPC focus on its core business and optimize its asset structure.The selling price will be determined according to the secondary market price of the time.

HKG:9887SHA:600422
Asia

Nanjing Leads Biolabs' Research Results Selected for 2026 Oncology Meeting Presentations

Six of Nanjing Leads Biolabs' (HKG:9887) latest research results were selected to be presented at the 2026 annual meeting of the European Society for Medical Oncology.Two were chosen for oral presentation, while four were selected for poster presentations covering extrapulmonary neuroendocrine carcinoma, biliary tract cancer, relapsed/refractory multiple myeloma, and other therapeutic areas.The company has also been granted late-breaking abstract (LBA) eligibility and will submit the full LBA in September 2026.The conference will be held in Madrid, Spain, from October 23 to 27.

HKG:9887
Asia

Nanjing Leads Biolabs' Cancer Drug Included in China Regulator's Priority Review List

Nanjing Leads Biolabs' (HKG:9887) biologics license application for LBL-024 was approved for inclusion in priority review and approval procedure by China's National Medical Products Administration.The drug has been developed as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma, according to a Friday Hong Kong bourse filing.

HKG:9887
Asia

Nanjing Leads Biolabs Trustee to Buy Up to $50 Million in Shares Under Award Scheme; Shares Up 4%

Nanjing Leads Biolabs (HKG:9887) said its trustee will acquire up to $50 million of the company's H-shares through on-market transactions under its H-share award scheme, according to a Wednesday Hong Kong bourse filing.Shares of the biotech company were up nearly 4% in Thursday morning trade.The purchased shares will be used for future share awards to eligible participants, subject to vesting conditions under the scheme.Leads Biolabs said the share purchases are intended to enhance flexibility in compensation arrangements and help attract and retain talent.

HKG:9887
Asia

Nanjing Leads Biolabs Wins China Approval for Phase 3 Neuroendocrine Cancer Trial

Nanjing Leads Biolabs (HKG:9887) received approval from China's National Medical Products Administration to commence a Phase 3 clinical study of LBL-024 for advanced extrapulmonary neuroendocrine carcinoma, according to a Tuesday Hong Kong bourse filing.The study will evaluate LBL-024, a PD-L1/4-1BB bispecific antibody, in combination with platinum-based chemotherapy as a first-line treatment for patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC).

HKG:9887
Asia

Nanjing Leads Biolabs Enrolls First Patient in Phase 2 Study of Gastric Cancer Drug

Nanjing Leads Biolabs (HKG:9887) said it enrolled the first patient in the phase 2 clinical study of its cancer drug LBL-024, according to a Hong Kong bourse filing Tuesday.The firm will evaluate the drug, which is also known as Opamtistomig, for the treatment of first-line locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

HKG:9887

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:9887 in your portfolio
WheelAI
WheelAI
Analyze HKG:9887 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:9887